Clinical and economic burden of emergency department presentations for neutropenia following outpatient chemotherapy for cancer in victoria, Australia

Oncologist

Volumn 17, Issue 7, 2012, Pages 998-1004

  Livingston, Patricia M ^a   Craike, Melinda ^a   Slavin, Monica ^b,c,d  

^a DEAKIN UNIVERSITY   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cancer; Clinical burden; Economics; Emergency department; Financial charges; Neutropenia; Oncology

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; EMERGENCY HEALTH SERVICE; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL CHARGE; HOSPITAL PATIENT; HOSPITALIZATION COST; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC AGENTS; AUSTRALIA; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; OUTPATIENTS; RETROSPECTIVE STUDIES;

EID: 84864063899     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0456     Document Type: Article

References (26)

1. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.
2. Lingaratnam S, Slavin MA, Mileshkin L et al. An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Intern Med J 2011;41:110-120. doi: 10.1111/j.1445-5994.2010.02342.x.
3. Livingston PM, Craike M, Considine J. Presentation to emergency departments due to chemotherapy induced complications: Opportunities for improving service delivery. Australas Emerg Nurs J 2011;14:62-68. doi: 10.1016/j.aenj.2011.03.005.
4. Kuderer NM, Dale DC, Crawford J et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-2266.
5. Courtney M, Aldeen AZ, Gorman SM et al. Cancerassociated neutropenic fever: Clinical outcome and economic costs of emergency department care. The Oncologist 2007;12:1019-1026.
6. Freifield AG, Sepkowitz KA. No place like home? Outpatient management of patients with febrile neutropenia and low risk. J Clin Oncol 2011;29:3952-3954.
7. Carstensen M, Sorensen JB. Outpatient management of febrile neutropenia: Time to revise the present treatment strategy. J Support Oncol 2008;6:199-208.
8. Mayordomo JI, López A, Viñolas N et al.; ENIA Study Group. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 2009;25:2533-2542.
9. Australian Bureau of Statistics. Population Projections, Australia 2006 to 2101. Cat. No. 3222.0. Canberra, Australia: ABS, 2008:1-100.
10. Australian Institute of Health and Welfare. Cancer in Australia 2010: An Overview. Cancer Series No. 60. Cat. No. CAN 56. Canberra, Australia: AIHW, 2010:1-228.
11. Australian Institute of Health and Welfare. Australia's Health 2010. Cat. No. AUS 122. Canberra, Australia: AIHW, 2010:1-579.
12. Hendricks AM, Loggers ET, Talcott JA. Costs of home versus inpatient treatment for fever and neutropenia: Analysis of a multicenter randomized trial. J Clin Oncol 2011;29:3984-3989.
13. Lathia N, Mittmann N, DeAngelis C et al. Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 2010;116:742-748.
14. Weycker D, Malin J, Kim J et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study. Clin Ther 2009;31:1069-1081.
15. Lingaratnam S, Worth LJ, Slavin MA et al. A cost analysis of febrile neutropenia management in Australia: Ambulatory v. in-hospital treatment. Aust Health Rev 2011;35:491-500.
16. Craike M, Livingston PM, Considine J. Emergency department presentations of patients from culturally and linguistically diverse backgrounds (CALDB) receiving chemotherapy in day oncology settings. Australas Emerg Nurs J 2010;13:111-116.
17. Department of Health and Ageing. State of Our Public Hospital Report. Canberra, Australia: Department of Health and Ageing, 2009:1-96.
18. Australian Bureau of Statistics. Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia-Data only, 2006 (No. 2033.0.55. 001). Available at http://www.abs.gov.au/AUSSTATS/ abs@.nsf/DetailsPage/2033.0.55.001;2006, accessed March 5, 2010.
19. Australian Bureau of Statistics. 2039.0-Information Paper: An Introduction to Socio-Economic Indexes for Areas (SEIFA), Australia. Canberra, Australia: Australian Bureau of Statistics, 2006:1-53.
20. Ogle KS, Swanson GM, Woods N et al. Cancer and comorbidity: Redefining chronic diseases. Cancer 2000; 88:653-663.
21. Yu XQ, O'Connell DL, Gibberd RW et al. Assessing the impact of socio-economic status on cancer survival in New South Wales, Australia 1996-2001. Cancer Causes Control 2008;19:1383-1390.
22. Department of Human Services. Victoria's Cancer Action Plan 2008-2011. Melbourne, Australia: State Government of Victoria, Melbourne, 2008:1-72.
23. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004;39(suppl 1):S32-S37.
24. Teuffel O, Ethier MC, Alibhai SM et al. Outpatient management of cancer patients with febrile neutropenia: A systematic review and meta-analysis. Ann Oncol 2011;22:2358-2365.
25. Talcott JA, Yeap BY, Clark JA et al. Safety of early discharge for low-risk patients with febrile neutropenia: A multicenter randomized controlled trial. J Clin Oncol 2011;29:3977-3983.
26. Clinical Costing Standards Committee. Clinical Costings Standards of Australia, Clinical Costings Standards 2, Version 1.2.7. Melbourne, Australia: Clinical Costing Standards Committee, 2010:1-3.